UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2007

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is a large

accelerated filer, an accelerated filer, or a non-accelerated filer. See

definition of "accelerated filer and large accelerated filer" in

Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer X

Accelerated filer Non-accelerated

filer

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At October 31, 2007, 6,829,805,073 shares of the

issuer's voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

September 30, 2007

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements

Condensed

Consolidated Statements of Income for the three months and nine months ended September

30, 2007, and October 1, 2006

Condensed Consolidated

Balance Sheets as of September 30, 2007, and December 31, 2006

Condensed

Consolidated Statements of Cash Flows for the nine months ended September 30,

2007, and October 1, 2006

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

20

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

21

Item 3.

Quantitative

and Qualitative Disclosures About Market Risk

52

Item 4.

Controls and

Procedures

52

PART II. OTHER

INFORMATION

Item 1.

Legal

Proceedings

52

Item 1A.

Risk Factors

56

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

57

Item 3.

Defaults Upon

Senior Securities

57

Item 4.

Submission of

Matters to a Vote of Security Holders

57

Item 5.

Other

Information

57

Item 6.

Exhibits

58

Signature

59

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three

Months Ended

Nine

Months Ended

(millions, except per common share

data)

Sept. 30,

2007

Oct. 1,

2006

Sept. 30,

2007

Oct. 1,

2006

Revenues

11,990

12,280

35,548

35,768

Costs and expenses:

Cost of sales(a)

4,618

1,962

8,614

5,423

Selling,

informational and administrative expenses(a)

3,768

3,751

10,973

11,027

Research and

development expenses(a)

1,999

1,902

5,829

5,187

Amortization of

intangible assets

774

798

2,372

2,446

Acquisition-related

in-process research and development charges

--

--

283

513

Restructuring

charges and acquisition-related costs

455

249

2,318

816

Other

(income)/deductions - net

(260)

(343)

(1,149)

(958)

Income from

continuing operations before (benefit)/provision for taxes on income and

minority interests

636

3,961

6,308

11,314

(Benefit)/provision

for taxes on income

(161)

717

800

1,769

Minority

interests

10

Income from

continuing operations

796

3,239

5,502

9,535

Discontinued

operations:

Income from

discontinued operations - net of tax

--

120

--

330

Gains/(losses)

on sales of discontinued operations - net of tax

(35)

(82)

23

Discontinued

operations - net of tax

(35)

123

(82)

353

Net income

761

3,362

5,420

9,888

Earnings per common share - basic:

Income from

continuing operations

0.12

0.45

0.79

1.31

Discontinued

operations - net of tax

(0.01)

0.02

(0.01)

0.05

Net income

0.11

0.47

0.78

1.36

Earnings per common share -

diluted:

Income from

continuing operations

0.12

0.44

0.79

1.30

Discontinued

operations - net of tax

(0.01)

0.02

(0.01)

0.05

Net income

0.11

0.46

0.78

1.35

Weighted-average

shares used to calculate earnings per common share:

Basic

6,875

7,228

6,964

7,275

Diluted

6,894

7,251

6,986

7,306

Cash dividends paid per common

share

0.29

0.24

0.87

0.72

(a)

Exclusive of amortization of

intangible assets, except as disclosed in Note 11B. Goodwill and

Other Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

Sept. 30,

2007*

Dec. 31,

2006**

ASSETS

Cash and cash equivalents

2,611

1,827

Short-term investments

19,687

25,886

Accounts receivable, less allowance

for doubtful accounts

9,942

9,392

Short-term loans

526

514

Inventories

5,210

6,111

Prepaid expenses and taxes

3,749

3,157

Assets held for sale

115

62

Total current assets

41,840

46,949

Long-term

investments and loans

4,922

3,892

Property, plant and equipment, less

accumulated depreciation

15,714

16,632

Goodwill

21,210

20,876

Identifiable

intangible assets, less accumulated amortization

20,998

24,350

Other assets,

deferred taxes and deferred charges

4,346

2,138

Total assets

109,030

114,837

LIABILITIES

AND SHAREHOLDERS' EQUITY

Short-term borrowings, including

current portion of long-term debt

2,645

2,434

Accounts payable

2,298

2,019

Dividends payable

2,055

Income taxes payable

266

6,466

Accrued compensation and related

items

1,628

1,903

Other current liabilities

7,489

6,510

Liabilities held for sale

--

Total current liabilities

14,328

21,389

Long-term debt

6,041

5,546

Pension benefit

obligations

3,319

3,632

Postretirement

benefit obligations

1,957

1,970

Deferred taxes

7,544

8,015

Other taxes

payable

5,816

--

Other

noncurrent liabilities

3,415

2,927

Total liabilities

42,420

43,479

Shareholders' equity

Preferred stock

103

141

Common stock

442

441

Additional

paid-in capital

69,832

69,104

Employee

benefit trust, at fair value

(577)

(788)

Treasury stock

(54,346)

(46,740)

Retained

earnings

51,063

49,669

Accumulated

other comprehensive income/(expense)

93

(469)

Total shareholders' equity

66,610

71,358

Total liabilities and shareholders'

equity

109,030

114,837

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine

Months Ended

(millions of dollars)

Sept. 30,

2007

Oct. 1,

2006

Operating

Activities:

Net income

5,420

9,888

Adjustments to

reconcile net income to net cash provided by operating activities:

Depreciation

and amortization

4,084

4,026

Share-based

compensation expense

335

506

Acquisition-related

in-process research and development charges

283

513

Asset write-offs

associated with exiting Exubera

2,220

--

Gains on

disposal of investments, products and product lines

(89)

(201)

(Gains)/losses

on sales of discontinued operations

139

(37)

Deferred taxes

from continuing operations

(1,969)

(1,333)

Other deferred

taxes

--

67

Other non-cash

adjustments

343

180

Changes in

assets and liabilities (net of businesses acquired and divested)

(1,180)

(491)

Net cash provided by operating

activities

9,586

13,118

Investing Activities:

Purchases of

property, plant and equipment

(1,218)

(1,438)

Purchases of

short-term investments

(16,606)

(8,472)

Proceeds from

redemptions of short-term investments

23,426

17,346

Purchases of

long-term investments

(1,406)

(835)

Proceeds from redemptions

of long-term investments

173

229

Purchases of

other assets

(93)

(118)

Proceeds from

sales of other assets

29

Proceeds from

the sales of businesses, products and product lines

21

22

Acquisitions,

net of cash acquired

(464)

(1,989)

Other investing

activities

(268)

(82)

Net cash provided by investing

activities

3,594

4,666

Financing Activities:

Increase in

short-term borrowings, net

130

993

Principal

payments on short-term borrowings

(744)

(11,721)

Proceeds from

issuances of long-term debt

1,243

1,051

Principal

payments on long-term debt

(61)

(55)

Purchases of

common stock

(7,494)

(4,496)

Cash dividends

paid

(6,021)

(5,211)

Stock option

transactions and other

537

593

Net cash used

in financing activities

(12,410)

(18,846)

Effect of

exchange-rate changes on cash and cash equivalents

14

(8)

Net increase/(decrease)

in cash and cash equivalents

784

(1,070)

Cash and cash

equivalents at beginning of period

1,827

2,247

Cash and cash

equivalents at end of period

2,611

1,177

Supplemental

Cash Flow Information:

Cash paid

during the period for:

Income taxes

4,207

2,031

Interest

465

579

See

accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of

Presentation

We prepared the condensed

consolidated financial statements following the requirements of the Securities

and Exchange Commission (SEC) for interim reporting. As permitted under those

rules, certain footnotes or other financial information that are normally

required by accounting principles generally accepted in the United States of

America (GAAP) can be condensed or omitted. Balance sheet amounts and operating

results for subsidiaries operating outside the U.S. are as of and for the

three-month and nine-month periods ended August 26, 2007, and August 27, 2006.

We made certain minor

reclassifications to prior period amounts to conform to the third-quarter 2007

presentation.

Revenues, expenses, assets and

liabilities can vary during each quarter of the year. Therefore, the results

and trends in these interim financial statements may not be representative of

those for the full year.

We are responsible for the unaudited

financial statements included in this document. The financial statements

include all normal and recurring adjustments that are considered necessary for

the fair presentation of our financial position and operating results.

The information included in this

Quarterly Report on Form 10-Q should be read in conjunction with the

consolidated financial statements and accompanying notes included in Pfizer's

Annual Report on Form 10-K for the year ended December 31, 2006.

Note 2. Asset Impairment Charges

and Other Costs Associated with Exiting Exubera

In the third quarter of 2007, after

an assessment of the financial performance of Exubera, an inhalable form of

insulin for the treatment of diabetes, as well as its lack of acceptance by

patients, physicians and payers, we decided to exit the product and recorded

charges totaling $2.8 billion ($2.1 billion net of tax).

Total pre-tax charges for the three

months and nine months ended September 30, 2007, as well as the income statement

line items in which the various charges are recorded, are as follows:

(millions

of dollars)

Customer

Returns -

Revenues

Cost

of

Sales

Selling

Informational &

Administrative

Expenses

Research

Development

Total

Intangible

asset impairment charges

--

1,064

41

--

1,105

Inventory

write-offs

--

661

--

--

661

Fixed assets

impairment charges

--

451

--

454

Other exit

costs(a)

10

404

42

128

584

Total

10

2,580

83

131

2,804

(a)

On

the balance sheet primarily included in Other current liabilities.

The asset write-offs of

$2.2 billion (intangibles, inventory and fixed assets) represent non-cash

charges. The other exit costs, primarily contract and other termination costs, among

other liabilities, will result in future cash expenditures and are associated

with marketing and research programs, as well as manufacturing operations

related to Exubera. We expect that substantially all of the cash spending will

occur within the next year. During the implementation of the exit strategy,

certain additional cash costs will be incurred and reported in future periods,

such as maintenance-level operating costs. However, those future costs are not

expected to be significant. We expect that substantially all exit activities

will be completed within the next year.

Note 3. Adoption of New

Accounting Policy

As of January 1, 2007, we adopted the provisions of Financial Accounting

Standards Board (FASB) Interpretation No. 48 (FIN 48), Accounting for

Uncertainty in Income Taxes, an interpretation of SFAS 109, Accounting for

Income Taxes, and supplemented by FASB Financial Staff Position FIN

48-1, Definition of Settlement in FASB Interpretation No. 48, issued May

2, 2007, and changed our policy related to the accounting for income tax

contingencies. To understand the cumulative effect of these accounting changes,

see Note 7A. Taxes on Income: Adoption of New Accounting

Standard.

We continue to account for income tax

contingencies using a benefit recognition model. Beginning January

1, 2007, if we consider that a tax position is 'more likely than not' of being

sustained upon audit, based solely on the technical merits of the position, we

recognize the benefit. We measure the benefit by determining the amount that is

greater than 50% likely of being realized upon settlement, presuming that the

tax position is examined by the appropriate taxing authority that has full

knowledge of all relevant information. These assessments can be complex and we

often obtain assistance from external advisors.

Under the benefit recognition model, if our initial assessment

fails to result in the recognition of a tax benefit, we regularly monitor our

position and subsequently recognize the tax benefit: (i) if there are changes

in tax law or analogous case law that sufficiently raise the likelihood of

prevailing on the technical merits of the position to more likely than not;

(ii) if the statute of limitations expires; or (iii) if there is a completion

of an audit resulting in a favorable settlement of that tax year with the

appropriate agency. We regularly reevaluate our tax positions based on the

results of audits of federal, state and foreign income tax filings, statute of

limitations expirations, and changes in tax law that would either increase or

decrease the technical merits of a position relative to the more likely than

not standard.

Liabilities associated with uncertain tax positions are now classified as

current only when we expect to pay cash within the next 12 months. Interest and

penalties, if any, continue to be recorded in (Benefit)/provision for taxes

on income and are classified on the balance sheet with the related tax

liability.

Prior to 2007, our policy had been to account for income tax

contingencies based on whether we determined our tax position to be 'probable'

under current tax law of being sustained, as well as an analysis of potential

outcomes under a given set of facts and circumstances. In addition, we

previously considered all tax liabilities as current once the associated tax

year was under audit.

Note 4. Acquisitions

In the first quarter of 2007, we

acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical

company with a number of diabetes candidates and a novel technology platform

for developing new protein drug candidates, and Embrex, Inc., an animal health

company that possesses a unique vaccine delivery system known as Inovoject that

improves consistency and reliability by inoculating chicks while they are still

in the egg. In connection with these and other smaller acquisitions, we

recorded $283 million in Acquisition-related in-process research and

development charges in the first quarter of 2007.

In the second quarter of 2006, we completed the acquisition of all the

outstanding shares of Rinat Neuroscience Corp., a biologics company with

several new central-nervous-system product candidates. In connection with this

and other smaller acquisitions, we recorded $513 million in Acquisition-related

in-process research and development charges in the second quarter of 2006.

On February 28, 2006, we completed

the acquisition of the sanofi-aventis worldwide rights, including patent rights

and production technology, to manufacture and sell Exubera, an inhaled form of

insulin and the insulin-production business and facilities located in

Frankfurt, Germany, previously jointly owned by Pfizer and sanofi-aventis, for

approximately $1.4 billion (including transaction costs). All assets recorded

in connection with this acquisition (other than the $166 million allocated to

Pharmaceutical goodwill) have now been written off. See Note 2. Asset

Impairment Charges and Other Costs Associated with Exiting Exubera. Prior

to the acquisition, in connection with our collaboration agreement with

sanofi-aventis, we recorded a research and development milestone due to us from

sanofi-aventis of $118 million ($71 million, after tax) in the first

quarter of 2006 in Research and development expenses upon the approval

of Exubera in January 2006 by the Food and Drug Administration (FDA).

Note 5. Discontinued

Operations

The following amounts, primarily related

to our Consumer Healthcare business which was sold in December 2006 for $16.6 billion,

have been segregated from continuing operations and included in Discontinued

operations - net of tax in the condensed consolidated statements of income:

Three

Months Ended

Nine

Months Ended

(millions

of dollars)

Sept. 30,

2007

Oct. 1,

2006

Sept. 30,

2007

Oct. 1,

2006

Revenues

--

974

--

2,920